More than 100 years later after being firstly described, Chagas disease 26 remains endemic in 21 Latin American countries and has spread to other continents. 27
INTRODUCTION 50
American trypanosomiasis, also known as Chagas disease (CD), was described 51 in 1909 by the Brazilian researcher Carlos Chagas (1). More than 100 years later, this 52 neglected tropical disease, caused by the protozoan parasite Trypanosoma cruzi, 53 remains endemic in 21 countries from Latin America according to the WHO (2). 54
Moreover, although the disease was confined to the Region of the Americas, over the 55 last century, it has spread to other continents mainly due to human migration (3). 56
The disease has an acute phase that occurs immediately after the infection and 57 is usually asymptomatic/oligosymptomatic. The extent of parasite proliferation is 58 controlled by a competent host immune response, although the patient remains 59 chronically infected if untreated. Many of them could remain asymptomatic, but 30-40% 60 develop a severe stage that is mainly characterized by cardiac and/or gastrointestinal 61 pathologies (4). Chemotherapy is highly recommended for all acute and chronic 62 asymptomatic infected patients, but the current drugs, nifurtimox and benznidazole, are 63 far from adequate due to side effects and their poor efficacy in all clinical phases 64 (especially inactive against the chronic phase), besides the occurrence of naturally 65 resistant parasite strains belonging to some different discrete typing units (DTUs) (5) . 66
For these reasons, the search for effective, well-tolerated and affordable CD 67 drugs is both urgent and of genuine importance. However, despite significant advances 68 in the discovery and development of new effective drugs for this tropical disease, it 69 remains an unmet clinical need (6, 7) and for many patients there is no effective 70 treatment. This paper describes the therapeutic potential of a class of imidazole 71 compounds discovered to have anti-protozoan activity in a previous screening against 72 different trypanosomatids of different human PDE inhibitors from our in-house chemical 73 library (8). Compounds from this chemical class showed potential utility in Parkinson's 74 disease due to its ability to inhibit mammalian cyclic nucleotide PDE10A (9). Results 75 from the previous phenotypic screen of a focused library of 69 imidazole derivatives in 76 4 a panel of three pathogenic trypanosomatids, T. brucei, T. cruzi and L. infantum, 77 highlighted these imidazoles as promising hits for the development of anti-Leishmania 78 therapy (8). Interestingly, twelve members of this library (compounds 1-12) showed 79 also promising activities against the intracellular forms of T. cruzi (Tulahuen-β-80 galactosidase-transfected parasites, DTU VI), some of them being in a quite similar 81 potency as benznidazole (Bz; IC 50 = 3.18 µM) ( Table S1 from the Supplemental  82 Material), justifying further analysis of their potential against T. cruzi, including chemical 83
optimization. 84
The work presented here includes an evaluation of the mechanism of action of 85 this compound class, and initial efforts towards hit optimization and the development of 86 a structure-activity relationship (SAR). 87
88

RESULTS
89
Optimization of imidazole hit compounds. The first priority of the present 90 work was to improve the drug-like properties of the imidazoles with the most interesting 91 anti-T. cruzi activities. In order to improve aqueous solubility, we decided to increase 92 the polarity, designing a new serie of imidazole-related compounds with a reduced 93 number of aromatic rings as substituents on the heterocyclic core and introducing a 94 polar group such as the urea moiety. 95
The first synthetic approach to obtain these newly designed compounds used 96 different aminothiazole and aminoimidazole derivatives as starting material, together 97 with different isocyanates to easily synthesize the corresponding urea in one step, by 98 microwave irradiation in tetrahydrofuran (THF) with low to moderate yields (Figure 1) . 99
The second approach was focused on a 4-phenyl-2-amino imidazole scaffold and 100 employed a two-step synthesis based on the use of 1,1'-carbonyldiimidazole (CDI) as 101 reagent to convert the amino group into urea. After addition of CDI to the 102 aminoimidazole, the amine is activated and a carbonyl group added. The addition of Table 1 ] 124 125 Activity against bloodstream trypomastigotes. In order to verify the 126 therapeutic potential of this new compound class, we phenotypically assayed the 127 original imidazole hits (1-12) (Table S1) and the most promising of the new 4-phenyl, 2-128 ureaimidazoles 23, 31, 33, 37 and 38 (i.e. all the derivatives with an IC 50 below 10 µM) 129 against the other parasite form relevant for the mammalian infection (bloodstream 130 6 trypomastigotes -BT). To address the possibility that the compounds might not be 131 effective against other T. cruzi DTUs, we assayed also another strain from a different 132 DTU (Y strain -DTU II) for this assay. We found that 5 of the 17 compounds tested 133 showed greater activity than Bz (IC 50 = 12.9 ± 1.9 µM) against Y strain BT, with IC 50 134 values ranging 1.2 -11.5 µM (Table 2 ). Compound stood out as the most active against 135 this life-cycle stage (IC 50 = 1.2 ± 0.3 µM). As heart muscle is an important target for T. 136 cruzi infection and inflammation, we also investigated the potential toxicity of these 137 compounds towards primary cultures of mouse cardiac cells. As shown in Table 2 , 138 most compounds were not cardiotoxic, exhibiting LC 50 values ranging from 65 up to > 139 200 µM. The selective index was calculated, showing 9 to be the most selective (SI > 140 85) followed by 33 (IC 50 = 4.6 ± 0.1 µM, SI > 44). As related imidazoles were found to be able to increase cAMP levels in Leishmania 156 promastigote cultures (8), we here tested whether compound 9 was similarly able to 7 increase the levels of this cyclic nucleotide in T. cruzi. With this aim, BT of Y strain 158 were incubated with either 2× or 5×EC 50 of this compound for 2.5 h, and both the 159 cellular cAMP content and the released cAMP in the medium determined. Cultures 160 incubated in parallel, either without test compound, or with known T. brucei PDE 161 inhibitors (NPD-001 (9) and NPD-008 (10)), served as negative and positive controls, 162
respectively. 163
Our data demonstrated that incubation with compound 9 dose-dependently increased 164 the intracellular content of cAMP (1.8-fold, P <0.05, and 2.5-fold of untreated control, P 165 <0.01, at 2× and 5×EC 50 , respectively) ( Figure 4A ). cAMP was also released from the 166 cells and could be measured in the medium; NPD-001, NPD-008 and compound 9 all 167 induced highly significant increases in the extracellular cAMP concentration relative to 168 the untreated control (P <0.001; Figure 4B ). Today, Chagas disease is no longer only a problem for Latin America but has become 174 a global public health threat. Current therapeutic options rely on only two (related: 175 nitrofuran or nitroimidazole) drugs, nifurtimox and benznidazole, that although active in 176 the acute phase of the disease, suffer from a significant decrease of efficacy in the 177 later, chronic stage. Moreover, it has been found that some clinical isolates have 178 acquired resistance to the nitro-heterocyclic compounds, and that other strains are 179 innately resistant to these drugs (11). This unsatisfactory situation has led to a 180 sustained effort including clinical trials with posaconazole, E1224, and fexinidazole (12-181 14), although today, no new drugs for Chagas disease are on the horizon (5). 182
Our aim in this work was the study of previously described anti-kinetoplastid hits 183
bearing an imidazole ring against T. cruzi, including an improvement in their 184 8 pharmaceutical profile through increased polarity. From an initial set of 69 imidazole 185 compounds, 12 derivatives showed promising activities against intracellular T. cruzi 186 amastigotes, and acceptable selectivity, and thus deserve future studies (Table S1) (8). 187
However, these imidazoles, all with multiple phenyl substitutions, suffer from sub-188 optimal solubility. With the aim of decreasing their lipophilicity, we developed a 189 medicinal chemistry strategy that, while retaining the core five-membered ring 190 showed that five (23, 31, 33, 37 and 38) displayed promising effects against 198 intracellular T. cruzi forms (Table 1) Validation measurements of the intracellular and extracellular cAMP content 219 after incubation BT with compound 9 were therefore conducted. These experiments 220
were conducted with trypomastigotes as it is impossible to separate out the cAMP of 221 the much bigger host cells from the cAMP inside amastigotes. Lacking an established 222 positive control for the stimulation of cAMP in T. cruzi, we utilized two well-223 characterized inhibitors of T. brucei PDE-B1/B2, NPD-001 and NPD-008 (9, 10), relying 224 on the very high level of structural conservation in PDEs between kinetoplastids (21, 225 22). As expected, both compounds induced a clear and highly significant increase in 226 the cellular cAMP concentration at concentrations of just 2x or 5x their EC 50 value. 227
Moreover, imidazole 9 similarly induced cAMP increases: 246% of the untreated 228 control at 5x EC 50 after just 2.5 h of incubation and despite a highly significant increase 229 in cAMP efflux. Interestingly, all three PDE inhibitors also stimulated the efflux of cAMP 230 from the trypomastigotes, significantly raising the cAMP concentration in the medium 231 over that of the control (P <0.001). The phenomenon of cAMP efflux has been 232 described for mammalian cells, where it is mediated by ABC-class transporters (23), 233 but to the best of our knowledge it has not been reported for protozoan cells, although 234
we have previously observed it in T. brucei and Leishmania species (24). The 235 increased efflux from the trypomastigotes clearly shows that this mechanism in part 236 compensates for the inhibition of phosphodiesterase activities in the cells; however, as 237 the cellular levels still increase significantly, we propose that the efflux mechanism was 238 saturated upon treatment with the PDE inhibitors, leading to toxic cAMP levels and cell 239 death, as previously demonstrated in T. brucei (9, 10) . 240
Our findings demonstrate a promising in vitro activity of a series of phenyl-241 substituted imidazole derivatives, several being very active against the different 242 parasite forms and strains, especially compound 9, which merits further studies in order 243 to contribute to the identification of novel therapies for Chagas disease. 244
245
MATERIALS AND METHODS 246
Compounds studied. Imidazoles 1-12 from Table S1 were prepared following 247 previously described procedures (25) test. The results were expressed as the difference in reduction between treated and 288 non-treated cells according to the manufacturer instructions, and the value of LC 50 289 (minimum concentration that reduces in 50% the cellular viability) was determined by 290 non-linear regression using a sigmoid curve with a variable slope (30). 291
Trypanocidal activity. BT of Y strain (5x10 6 /mL) were incubated for 24 h at 37 °C in 292 RPMI in the presence or absence of 1:3 serial dilutions of the compounds (0.2 -50 μM) 293 for determination of parasite death rates through the direct quantification of live 294 parasites by light microscopy. The IC 50 (compound concentration that reduces the 295 number of live parasites by 50%) was calculated by non-linear regression (31); 296
Selectivity index (SI) is expressed as the ratio between LC 50 (toxicity for mammalian 297 cells) and the IC 50 (activity upon the parasite). 298
Transmission Electron Microscopy. Bloodstream trypomastigotes from Y strain (5 × 299 10 6 parasites/mL) were treated with compound 9 for 2 h at the concentration 300 corresponding to its 24 h IC 50 value. The parasites were fixed with 2.5% glutaraldehyde 301 in 0.1 M Na-cacodylate buffer (pH 7.2) at room temperature for 40 min, and postfixed 302 with a solution of 1% OsO 4 , 0.8% potassium ferricyanide, and 2.5 mM CaCl 2 in the 303 same buffer for 30 min. The samples were washed in PBS, dehydrated in an ascending 304 acetone series, and embedded in epoxy resin. Ultrathin sections (Leica Ultracut; UCT; 305
Leica, Vienna, Austria) were stained with 2% uranyl acetate and lead citrate and 306 examined using an EM10C Zeiss microscope (Oberkochen, Germany) (32). 307 cAMP measurement. BT of Y strain (15x10 6 parasites/mL) were treated with 308 compound 9 in the concentration of 2x and 5x the IC 50 for 2.5 h at 37 °C. After the 309 incubation, the samples were centrifuged at 5000 rpm for 2 min and the supernatant 310 collected. The pellet was resuspended in 100 µL of HCl 0.1 M and incubated at 4 °C for 311 20 min, followed by centrifugation at 12000 rpm for 10 min and collection of the 312 supernatant. Samples were stored at -80 °C and then analyzed using a cAMP ELISA 313 kit (Cayman Chemicals, Michigan, USA) accordingly to the manufacturer instructions 314 (9). Each experiment was performed independently at least 3 times and all samples 315 
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Each value is the mean of two independent determinations. 457 458 
